Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists

• Published in: Pituitary Vol. 17; no. 5; pp. 441 - 449
• Main Authors: Barbosa, Flávia Regina Pinho, dos Santos Silva, Cintia Marques, Lima, Giovanna Aparecida Balarinni, Warszawski, Leila, Domingues, Romeu Cortes, Dominic, Michele, Fontes, Rosita, Neto, Leonardo Vieira, Gadelha, Mônica Roberto
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.10.2014; Springer Nature B.V
• Subjects: Adult; Aged; Body Mass Index; Dopamine Agonists - pharmacology; Dopamine Agonists - therapeutic use; Endocrinology; Female; Human Physiology; Humans; Hyperprolactinemia - drug therapy; Hyperprolactinemia - epidemiology; Male; Medicine; Medicine & Public Health; Middle Aged; Prolactin - blood; Prolactinoma - blood; Prolactinoma - complications; Prolactinoma - drug therapy; Prolactinoma - epidemiology; Sleep Apnea, Obstructive - blood; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - drug therapy; Sleep Apnea, Obstructive - epidemiology; Waist Circumference - drug effects; Young Adult; Prolactinoma; Obstructive sleep apnea; Hyperprolactinemia; Dopamine agonist

Objectives Obesity is the main risk factor for the development of obstructive sleep apnea (OSA). Hyperprolactinemia has also been related to obesity. To determine the OSA prevalence in patients with prolactinoma before and after dopamine agonist (DA) and to evaluate the correlation between the apnea...